Maria Sharapova revealed on Monday that she had failed a drugs test at this year’s Australian Open.
But what is known about the substance she was taking and why was the Russian taking it after The World Anti-Doping Agency (WADA) announced as far back as September 2015, of its intention to add the drug to the banned list?
Meldonium, also known as mildronate the name by which Sharapova knew the drug, is used to treat ischaemia, a condition which causes a lack of blood flow to parts of the body.
The drug increases blood flow of sufferers of the condition, but also improves exercise capacity in athletes which is why it was added to the WADA’s list of banned substances.
It is classed as an S4 substance under the Wada code, which addresses hormone and metabolic modulators and a memo was sent out to athletes by Russia’s anti-doping agency last September informing them of the decision to ban its use.
Sharapova says she has been taking the drug for 10 years after she was regularly falling ill, claiming she had a magnesium deficiency and family history of diabetes.
The International Tennis Federation (ITF) said she would be provisionally suspended from 12 March.
US sportswear giant Nike moved swiftly to suspend its sponsorship deal with the 28-year-old Russian tennis player.
The deal signed in 2010 is said to be worth $70m (£49m) plus commission on sales of her own branded clothes.
Ms Sharapova is the world’s highest paid female athlete after earning nearly $30m in 2015 from winnings and endorsements, according to Forbes.
Fellow Russian athlete and Olympic gold medalist figure skater Ekaterina Bobrova admitted to testing positive to the drug on Monday.
Subscribe to our newsletters
Every month Human Kinetics produces three unique email Newsletters, packed with great articles, events and news, plus information on our latest resources and exclusive reader offers. They’re completely free and if you change your mind you can unsubscribe at any time. So subscribe today.
Fill in your information below and check the emails you want.